In the presence of the President of the Republic, Emmanuel Macron, Sanofi inaugurated today in Neuville-sur-Saône (Rhône-Alpes) a new revolutionary production unit, called "Modulus", to produce its next vaccines and biological drugs. This new factory concept, entirely designed by Sanofi's industrial teams, is a world first. Modulus has the particularity of adapting to manufacture up to 4 vaccines or biomedicines simultaneously , and of being able to reconfigure itself in a few days or weeks to change technological platform (live attenuated viral vaccines, recombinant protein or messenger RNA vaccines, as well as treatments derived from biotechnologies such as enzymes or monoclonal antibodies), compared to several months or even years in conventional factories. The result of an investment of nearly 500 million euros , Modulus will be operational at the end of 2025, after qualification of the facilities and validation of the manufacturing processes. Sanofi plans to produce some of its future biomedicines and vaccines there.

Traditionally, an industrial vaccine or biomedicine site has buildings, each dedicated to a technology or product. Each element is built in solid form and cannot change once validated by the health authorities. This configuration prevents any rapid change in production capacities, for example to integrate the arrival of a new drug or quickly increase the production of a vaccine in the event of a pandemic. The uniqueness of Modulus lies in the very design of the building, which houses the equivalent of 34 standardized mini-factories, equipped with interconnected equipment, modular according to the required technology, in order to configure the production line corresponding to the needs of the moment.

 

Source: sanofi.com

Report Abuse